Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Holistic Study of second-line rituximab versus avatrombopag for immune thrombocytopenia
2023-505573-32-00Phase 3Authorised
- Sponsor
- Ostfold Hospital Trust
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in immune thrombocytopenia (ITP) comparing Rituximab with Avatrombopag (2 arms). Primary endpoint: Durable platelet response. Planned start Jul 2025; status: authorised.
02
Drugs
rituximabavatrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2023-505573-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505573-32-00.